Form 4: Climb Bio Director Thomas Stephen Basil Reports Share Transactions
SEC Form 4 Filing
Director Thomas Stephen Basil of Climb Bio, Inc. reports the conversion of restricted stock units into common stock on January 1, 2025.
Summary
- Thomas Stephen Basil, a director at Climb Bio, Inc., reported a transaction involving the conversion of restricted stock units (RSUs) into common stock.
- On January 1, 2025, 50,188 RSUs were converted into 50,188 shares of common stock.
- Following this transaction, Mr. Basil directly owns 154,095 shares of common stock.
- The RSUs were granted on June 27, 2024, and vest in three tranches: 50% on January 1, 2025, 25% on March 27, 2025, and the remaining 25% on June 27, 2025, contingent on continued service.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation. It is a neutral event with a slightly positive sentiment due to the continued service of the director.
Positives
- The vesting of RSUs indicates continued service and commitment from the director.
Industry Context
This is a standard SEC Form 4 filing, which is common for company insiders reporting transactions in their company's stock. It is a routine part of corporate governance and transparency.
Comparison to Industry Standards
- The vesting schedule of the RSUs, with tranches over a year, is a common practice in the industry for incentivizing and retaining key personnel.
- The reporting of the transaction via SEC Form 4 is a standard requirement for directors and officers of publicly traded companies, ensuring transparency and compliance with securities regulations.
- Similar filings are made by directors and officers of comparable companies such as Alnylam Pharmaceuticals and Moderna, when they have transactions in their company's stock.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it indicates continued commitment from a key director.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date the restricted stock units were granted. |
| 01/01/2025 | Date of the reported transaction where 50% of the RSUs vested and were converted to common stock. |
| 03/27/2025 | Date when 25% of the RSUs will vest. |
| 06/27/2025 | Date when the remaining 25% of the RSUs will vest. |
| 01/03/2025 | Date the SEC Form 4 was signed. |
Keywords
Climb Bio, Director, Thomas Stephen Basil, Restricted Stock Units, RSU, Common Stock, Share Transaction, SEC Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.